Compare Msci Inc (MSCI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Summit Therapeutics Inc — how do they compare? Msci Inc trades at $554.53 (market cap $40.09B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Msci Inc is far larger — about 2.9× Summit Therapeutics Inc's market cap, and Msci Inc pays a 1.49% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MSCI | SMMT | |
|---|---|---|
Market Cap | $40.09B | $13.79B |
Sector | Financials | Health |
52-Week High | $643.83 | $26.38 |
52-Week Low | $511.84 | $12.43 |
Enterprise Value | $46.25B | $13.11B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent Q2 2026 earnings slightly missed expectations, but the company maintains robust profitability and a $2.05 dividend. Analyst consensus is bullish with a $728.14 price target, though technical indicators suggest near-term pressure with support at $545.
Outlook remains positive driven by high-margin recurring revenue and strategic acquisitions like First Street. Risks include elevated debt levels and market sensitivity. Institutional sentiment is strong with 73% buy ratings, positioning MSCI for long-term growth despite current technical weakness.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
